AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Study acronym: VECTRA-01
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Feb 13, 2029 → Jun 4, 2029
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 132 → 151 locations
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 6 of 7 entries
  2. Primary completion pushed from Feb 13, 2029 to Jun 4, 2029v3 Show 5 more changesShow less
    • Trial sites expanded: 104 → 132 locations
    • Study completion pushed from Dec 20, 2029 to Jun 6, 2030
    • Interventions: AZD2265 (Drug), Abiraterone (Drug), Apalutamide (Drug), Cabazitaxel (Drug), Darolutamide (Drug), Enzalutamide (Drug), Radium-223 (Drug)… to Abiraterone (Drug), Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) (Drug), Apalutamide (Drug), Cabazitaxel (Drug), Darolutamide…
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description shortened, about 1 word
  3. Trial sites expanded: 90 → 104 locationsv2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
729 trials monitored
See 62 trials at risk
Prostate Cancer
2,550 trials monitored
See 165 trials at risk
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Trial Details
NCT Number NCT07611110
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Metastatic Castration-resistant Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 670 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov